Holen Sie sich die Stockscreener-App
9.23
2.33%
0.21
Handel nachbörslich:
9.19
-0.04
-0.43%
Schlusskurs vom Vortag:
$9.02
Offen:
$8.93
24-Stunden-Volumen:
1.06M
Relative Volume:
1.73
Marktkapitalisierung:
$564.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-10.99
EPS:
-0.84
Netto-Cashflow:
$-23.97M
1W Leistung:
+3.82%
1M Leistung:
+63.65%
6M Leistung:
+380.73%
1J Leistung:
+573.72%
1-Tages-Spanne:
$8.87
$9.44
1-Wochen-Bereich:
$7.91
$9.44
52-Wochen-Spanne:
$1.23
$9.44
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by StockNews.com - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 By Investing.com - Investing.com Canada
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month HighHere's What Happened - MarketBeat
Where are the Opportunities in (CRVS) - Stock Traders Daily
Insiders Rewarded With US$3.9m Addition To Investment As Corvus Pharmaceuticals Stock Hits US$480m - Simply Wall St
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6%Here's Why - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.com - MarketBeat
Corvus Pharmaceuticals secures new South San Francisco lease - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 52-Week HighShould You Buy? - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 By Investing.com - Investing.com Australia
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 - Investing.com India
CRVS Hits 52-week High Ahead Of Atopic Dermatitis Trial Results - RTTNews
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment - Yahoo Finance
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Slidee, Closing at 6.72 - The Dwinnex
Short Interest in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Expands By 31.1% - MarketBeat
Was Corvus Pharmaceuticals Inc (CRVS)’s session last reading good? - US Post News
Corvus Pharmaceuticals Inc (CRVS) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Taking a Closer Look At Corvus Pharmaceuticals Inc (CRVS) Following Its Recent Trade - Knox Daily
Corvus Pharmaceuticals stock soars to 52-week high of $6.17 By Investing.com - Investing.com Australia
Corvus Pharmaceuticals stock soars to 52-week high of $6.17 - Investing.com India
StockNews.com Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell - MarketBeat
Corvus Pharmaceuticals Inc [CRVS] insider makes an insider purchase of 20,000 shares worth 34624.0. - Knox Daily
Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily
Point72 Asset Management L.P. Acquires Shares of 5,964,510 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" at StockNews.com - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World
Cormorant Asset Management's Strategic Acquisition in Corbus Pha - GuruFocus.com
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High at $43.81 - Defense World
Cormorant asset management buys $7m in Corbus Pharmaceuticals stock By Investing.com - Investing.com Canada
Closing Figures Unveiled: Corvus Pharmaceuticals Inc (CRVS) Drop -7.95, Closes at 5.44 - The Dwinnex
A stock that deserves closer examination: Corvus Pharmaceuticals Inc (CRVS) - US Post News
Are Smart Investors Making the Right Decision? Corbus Pharmaceuticals Holdings Inc (CRBP) - SETE News
Top investors say Corcept Therapeutics Inc (CORT) ticks everything they need - SETE News
Samlyn Capital LLC Has $11.14 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Wall Street Analyst Initiated Core Scientific Inc [CORZ]. What else is Wall St. saying - The DBT News
Where are the Opportunities in (CRBP) - Stock Traders Daily
Corcel shares drop as explorer raise funds and ups exposure in Angola - Proactive Investors USA
Corvus Pharmaceuticals Inc [CRVS] Stock bought by Insider Jones William Benton for $34624.0 - Knox Daily
Integral Health Asset Management LLC Invests $4.53 Million in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Spotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options Activity - Benzinga
Evergreen Capital Management LLC Purchases 1,441 Shares of Coterra Energy Inc. (NYSE:CTRA) - Defense World
How does CRBP’s price to cash per share ratio compare in the market? - US Post News
There is no way Corsair Gaming Inc (CRSR) can keep these numbers up - SETE News
Mizuho recommends buying Corbus following its drop post-Novo's obesity data (NASDAQ:CRBP) - Seeking Alpha
450,000 Shares in Core Scientific, Inc. (NASDAQ:CORZ) Bought by P Schoenfeld Asset Management LP - MarketBeat
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):